Skip to main content

Research with a destination | A question to investigate

A smaller research budget needs a sharper experiment.

A growing medicines business cannot investigate every uncertainty at once. We want to work with SMEs on research questions that protect scarce time and capital: the experiments that could change a product, service or investment decision.

Film credits

Find the assumption carrying the business case.

A founder may believe a new process will reduce waste, a service will attract repeat demand or a software tool will make a review easier. Those are different hypotheses, requiring different evidence. The first step is to identify which uncertain assumption matters most to the next decision. A technically elegant study can still be a poor use of money if it investigates a question the business does not need answered yet.

Make the decision explicit before the method.

A proposed collaboration would describe what happens if the result is positive, negative or inconclusive. That might mean proceeding to a feasibility batch, revising the service model or ending a development route. We would set a ceiling on time and resources before choosing the design. This gives the research a commercial purpose while preserving the independence needed to report an uncomfortable result rather than treating every outcome as encouragement.

Use the evidence that already exists carefully.

Initial inputs could include process records, customer interviews, previous experiments and published work, with permission to use each source. We would look for gaps and contradictions before commissioning new activity. An anecdote can reveal a useful problem but cannot establish how widespread it is. A public dataset can describe a market context but cannot confirm that a particular customer will buy. Distinguishing these roles helps prevent unnecessary studies.

Choose the cheapest fair comparison.

A bench test, structured interview study or retrospective workflow comparison may answer an early question without a large live pilot. The comparator should be the realistic alternative available to the business, including an existing supplier or an internal improvement. We would examine measurement error and practical constraints before promising precise conclusions. Sometimes a wider uncertainty range is more honest and more useful than a narrow estimate built on weak inputs.

A public decision brief | An illustrative example

Open the question.
Inspect the reasoning.

Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.

An academic or development team examining the next experiment after a published model comparison.

What does this result allow us to ask next?

A promising figure can sharpen a research question. Its value depends on keeping the model, observation and next hypothesis distinct.

A proposition to investigate

A clearer question can be a useful output.

An evidence brief could help a team distinguish a published observation from the experiment needed to investigate translation. The proposed value is a more precise comparison and an explicit evidence gap. It does not turn an external model result into a clinical claim or a NEUVIOR discovery.

This is a constructed research-planning question, not an agreed study or product-development result.

What the next brief would contain

A decision someone
can commission.

The decision
Whether a specific follow-on question has a credible experimental comparison.
The comparator
A scientifically justified model or condition relevant to the proposed hypothesis.
The evidence
Full methods, model relevance, measurements, replication and a feasible authorised protocol.
Stop or redesign
Stop or redesign if the proposed model cannot answer the question or the required work is not feasible.

Constructed public example | Not PHARMORIS-generated software output or a measured customer result.

Keep this example brief

Preserve enough detail to learn from failure.

A proposed study would record methods, exclusions, deviations and the reasoning behind changes. UKRI's integrity guidance provides research-conduct context; NPL's good-practice resources provide measurement context (UKRI, n.d.; National Physical Laboratory, n.d.). The project would use the relevant specialist methods rather than claiming general compliance from these references. A failed test can still become a useful asset if it identifies a limit, eliminates an expensive route or explains why a promising effect did not reproduce.

Know what a partner contributes.

The SME would bring its decision, constraints and authorised materials. Research collaborators could contribute methods, facilities or independent assessment where separately agreed. NEUVIOR's proposed contribution is to help connect the question, evidence and next decision. This is a discussion route, not a claim that every facility or specialist service is already available. Costs, responsibilities, rights and any necessary approvals would be settled before work starts.

End with a decision record rather than a longer wishlist.

The bounded output would be an evidence summary, a record of what was tested and a recommendation tied to the original decision. Expansion would require a result strong enough to justify the next cost, with uncertainties stated. We would stop if the method cannot distinguish the options, if access to essential inputs is unavailable or if the expected value of further learning is too small. The ambition is focused progress that a small team can afford.

A useful study budget would separate essential measurement from desirable exploration and identify which result would unlock each later expense. That gives a founder a way to sequence spending without treating uncertainty as a reason to investigate everything. The project can remain ambitious while making its first decision small enough to finance and clear enough to review.

Sources and context

UKRI (n.d.) Research integrity. Available at: https://www.ukri.org/manage-your-award/good-research-resource-hub/research-integrity/ (Accessed: 14 October 2026).

National Physical Laboratory (n.d.) Good practice guides. Available at: https://www.npl.co.uk/resources/gpgs (Accessed: 14 October 2026).

Another useful angle.

  • Public involvement in research

    Shape medicines research with the people affected, through proposed public-involvement partnerships that offer clear influence, support and feedback on decisions.

  • Reproducible medicines analysis

    Explore reproducible medicines analysis that connects source data, calculation and interpretation, giving research partners a result they can check and update.

  • Academic and commercial translation

    Connect an academic finding with a credible user, comparator and next experiment, while keeping research rights and commercial translation questions clear.

NEWSPerspectives & features